BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• 28
• 29
• 30
• 31

• 

  Drug Development

  Researchers ID How Common Liver Cancer Mutation Changes Cells

  Researchers with the Hubrecht Institute in Utrecht, Netherlands and Radboud University in Nijmegen, Netherlands, recently developed a human model using organoids to evaluate the function of specific genes commonly mutated in liver cancer.

  May 24, 2019

   · 

  2 min read

   · 

  Mark Terry
• 

  Business

  Dynavax to Lay Off 37% of Staff, CEO to Retire as Company Restructures

  Dynavax plans to step away from immuno-oncology development and will lay off 37% of its staff as a result.

  May 24, 2019

   · 

  3 min read

   · 

  Alex Keown
• 

  FDA

  Novocure Wins FDA Approval for First Mesothelioma Treatment in 15 Years

  Shares of NovoCure are up more than 6% in premarket trading after the company announced it won regulatory approval for its mesothelioma treatment, NovoTTF-100L System.

  May 24, 2019

   · 

  2 min read

   · 

  Alex Keown
• 

  Daiichi Sankyo Denies Report That It’s Selling Over-the-Counter Drug Unit

  On Thursday, Nikkei Business reported that Japan’s Daiichi Sankyo was in negotiations with several companies to sell its over-the-counter drug unit. The final price, Nikkei Business suggested, would hit around $900 million.

  May 24, 2019

   · 

  2 min read

   · 

  Mark Terry
• 

  Business

  Nektar Forms New Subsidiary in Anticipation of Opioid Medication Approval

  Inheris Biopharma was formed as Nektar awaits the FDA approval of a pain medication that does not have the euphoric side effects of other opioids.

  May 24, 2019

   · 

  2 min read

   · 

  Alex Keown
• 

  Deals

  Stoke Therapeutics Files for $86 Million IPO

  Stoke focuses on treating genetic diseases by upregulating protein expression. Its lead compound, STK-001, is focused on Dravet syndrome, a rare form of epilepsy that starts in infancy.

  May 24, 2019

   · 

  2 min read

   · 

  Mark Terry
• 

  Drug Development

  Tonix Pharma In-Licenses Drug to Treat Cocaine Intoxication

  New York City-based Tonix Pharmaceuticals announced it has in-licensed a Phase II drug, TNX-1300, from Columbia University. TNX-1300 is a recombinant enzyme that degrades and metabolizes cocaine in cocaine abusers.

  May 24, 2019

   · 

  3 min read

   · 

  Mark Terry
• 

  Policy

  White House to Issue Executive Order to Disclose Pricing Across the Health Care Industry

  The administration sees the push for transparency as a tool to help consumers control the costs of their health care.

  May 24, 2019

   · 

  2 min read

   · 

  Alex Keown
• 

  FDA

  Novartis’ SMA Gene Therapy Treatment Approved by FDA, Priced at $2.125 Million

  The price of the one-and-done gene therapy treatment is about half of what was initially projected by Novartis.

  May 24, 2019

   · 

  4 min read

   · 

  Alex Keown
• 

  Drug Development

  Clinical Catch-up from Last Week: May 20-24

  Here’s a roundup of some of the top clinical trial news from the previous week.

  May 24, 2019

   · 

  7 min read

   · 

  Mark Terry